Total Payments
$2.6M
2024 Payments
$335,574
Companies
18
Transactions
851
Payment Breakdown by Category
Research$1.4M (54.4%)
Consulting$594,690 (22.5%)
Other$473,742 (17.9%)
Travel$124,710 (4.7%)
Food & Beverage$14,373 (0.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.4M | 18 | 54.4% |
| Consulting Fee | $594,690 | 39 | 22.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $435,293 | 193 | 16.5% |
| Travel and Lodging | $124,710 | 357 | 4.7% |
| Honoraria | $38,450 | 19 | 1.5% |
| Food and Beverage | $14,373 | 225 | 0.5% |
Payments by Type
Research
$1.4M
18 transactions
General
$1.2M
833 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $1.4M | 4 | $0 (2021) |
| Emmaus Medical, Inc. | $565,812 | 40 | $0 (2024) |
| GlaxoSmithKline, LLC. | $450,653 | 485 | $0 (2024) |
| Supernus Pharmaceuticals, Inc. | $80,587 | 130 | $0 (2024) |
| Rhodes Pharmaceuticals L.P. | $50,616 | 86 | $0 (2018) |
| IRONSHORE PHARMACEUTICALS INC. | $29,839 | 46 | $0 (2024) |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | $12,361 | 10 | $0 (2024) |
| Duchesnay USA Incorporated | $10,318 | 9 | $0 (2020) |
| Otsuka America Pharmaceutical, Inc. | $6,663 | 9 | $0 (2024) |
| PFIZER INC. | $6,522 | 13 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $335,574 | 199 | Emmaus Medical, Inc. ($183,818) |
| 2023 | $235,965 | 176 | GlaxoSmithKline, LLC. ($126,502) |
| 2022 | $424,823 | 182 | Emmaus Medical, Inc. ($286,900) |
| 2021 | $632,456 | 151 | Eli Lilly and Company ($492,575) |
| 2020 | $957,533 | 23 | Eli Lilly and Company ($938,472) |
| 2019 | $8,519 | 28 | Ironshore Pharmaceuticals Inc. ($7,754) |
| 2018 | $22,131 | 46 | Rhodes Pharmaceuticals L.P. ($21,867) |
| 2017 | $28,849 | 46 | Rhodes Pharmaceuticals L.P. ($28,748) |
All Payment Transactions
851 individual payment records from CMS Open Payments — Page 1 of 35
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | Otsuka America Pharmaceutical, Inc. | — | Travel and Lodging | Cash or cash equivalent | $44.97 | General |
| 12/13/2024 | Otsuka America Pharmaceutical, Inc. | — | Consulting Fee | Cash or cash equivalent | $5,472.00 | General |
| 12/13/2024 | Otsuka America Pharmaceutical, Inc. | — | Travel and Lodging | Cash or cash equivalent | $72.00 | General |
| 12/12/2024 | REVANCE THERAPEUTICS, INC. | DAXXIFY (Drug) | Food and Beverage | In-kind items and services | $28.27 | General |
| Category: AESTHETICS AND THERAPEUTICS | ||||||
| 12/06/2024 | SANOFI PASTEUR INC. | — | — | In-kind items and services | $78.00 | Research |
| Study: A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 2arm study to investigate the safety of a 4-dose regimen of a 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers | ||||||
| 12/06/2024 | SANOFI PASTEUR INC. | — | — | In-kind items and services | $58.00 | Research |
| Study: A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 2arm study to investigate the safety of a 4-dose regimen of a 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers | ||||||
| 12/06/2024 | SANOFI PASTEUR INC. | — | — | In-kind items and services | $25.00 | Research |
| Study: A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 2arm study to investigate the safety of a 4-dose regimen of a 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers | ||||||
| 12/05/2024 | SANOFI PASTEUR INC. | — | — | In-kind items and services | $66.00 | Research |
| Study: A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 2arm study to investigate the safety of a 4-dose regimen of a 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers | ||||||
| 12/05/2024 | SANOFI PASTEUR INC. | — | — | In-kind items and services | $58.00 | Research |
| Study: A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 2arm study to investigate the safety of a 4-dose regimen of a 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers | ||||||
| 12/05/2024 | SANOFI PASTEUR INC. | — | — | In-kind items and services | $25.00 | Research |
| Study: A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 2arm study to investigate the safety of a 4-dose regimen of a 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers | ||||||
| 12/05/2024 | SANOFI PASTEUR INC. | — | — | In-kind items and services | $25.00 | Research |
| Study: A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 2arm study to investigate the safety of a 4-dose regimen of a 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers | ||||||
| 12/04/2024 | SANOFI PASTEUR INC. | — | — | In-kind items and services | $381.74 | Research |
| Study: A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 2arm study to investigate the safety of a 4-dose regimen of a 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers | ||||||
| 12/04/2024 | SANOFI PASTEUR INC. | — | — | In-kind items and services | $160.00 | Research |
| Study: A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 2arm study to investigate the safety of a 4-dose regimen of a 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers | ||||||
| 12/04/2024 | SANOFI PASTEUR INC. | — | — | In-kind items and services | $108.54 | Research |
| Study: A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 2arm study to investigate the safety of a 4-dose regimen of a 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers | ||||||
| 11/15/2024 | Emmaus Medical, Inc. | Endari (Drug) | Consulting Fee | Cash or cash equivalent | $1,800.00 | General |
| Category: Sickle Cell | ||||||
| 11/15/2024 | Otsuka America Pharmaceutical, Inc. | — | Food and Beverage | In-kind items and services | $27.28 | General |
| 11/15/2024 | Otsuka America Pharmaceutical, Inc. | — | Food and Beverage | In-kind items and services | $20.46 | General |
| 11/15/2024 | Otsuka America Pharmaceutical, Inc. | — | Food and Beverage | In-kind items and services | $15.88 | General |
| 11/14/2024 | Otsuka America Pharmaceutical, Inc. | — | Travel and Lodging | In-kind items and services | $729.68 | General |
| 11/14/2024 | Otsuka America Pharmaceutical, Inc. | — | Travel and Lodging | In-kind items and services | $218.86 | General |
| 11/14/2024 | Otsuka America Pharmaceutical, Inc. | — | Food and Beverage | In-kind items and services | $61.38 | General |
| 11/01/2024 | REVANCE THERAPEUTICS, INC. | DAXXIFY (Drug) | Food and Beverage | In-kind items and services | $127.94 | General |
| Category: AESTHETICS AND THERAPEUTICS | ||||||
| 09/25/2024 | GlaxoSmithKline, LLC. | BEXSERO (Biological) | Travel and Lodging | Cash or cash equivalent | $72.00 | General |
| Category: VACCINES | ||||||
| 09/25/2024 | GlaxoSmithKline, LLC. | BEXSERO (Biological) | Travel and Lodging | Cash or cash equivalent | $36.00 | General |
| Category: VACCINES | ||||||
| 08/05/2024 | GlaxoSmithKline, LLC. | BEXSERO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,900.00 | General |
| Category: VACCINES | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3819253 AND LY3832479 IN PARTICIPANTS WITH MILD TO MODERATE COVID-19 ILLNESS | Eli Lilly and Company | $1.1M | 3 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MONO AND COMBINATION THERAPY WITH MONOCLONAL ANTIBODIES IN PARTICIPANTS WITH MILD TO MODERATE COVID-19 ILLNESS (BLAZE-4) | Eli Lilly and Company | $350,579 | 1 |
| A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN MIGRAINE PREVENTION IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE | PFIZER INC. | $6,303 | 4 |
| A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 2arm study to investigate the safety of a 4-dose regimen of a 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers | SANOFI PASTEUR INC. | $985.28 | 10 |
About Corey Hebert
Corey Hebert is a Pediatrics healthcare provider based in Gretna, Louisiana. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/03/2006. The National Provider Identifier (NPI) number assigned to this provider is 1457368037.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Corey Hebert has received a total of $2.6M in payments from pharmaceutical and medical device companies, with $335,574 received in 2024. These payments were reported across 851 transactions from 18 companies. The most common payment nature is "" ($1.4M).
Ad
Practice Information
- Specialty Pediatrics
- Location Gretna, LA
- Active Since 08/03/2006
- Last Updated 08/28/2008
- Taxonomy Code 208000000X
- Entity Type Individual
- NPI Number 1457368037
Products in Payments
- Endari (Drug) $565,812
- BEXSERO (Biological) $450,653
- Aptensio XR (Drug) $50,616
- QELBREE (Drug) $40,896
- Qelbree (Drug) $36,791
- JORNAY PM (Drug) $22,085
- Siklos (Drug) $10,318
- Jornay PM 20mg capsules (Bottle of 100) (Drug) $7,754
- NURTEC ODT (Drug) $6,303
- EUCRISA (Drug) $219.36
- DAXXIFY (Drug) $156.21
- SYNAGIS (Biological) $115.23
- Oralair (Drug) $80.83
- HUMIRA (Biological) $25.36
- Azstarys (Drug) $24.25
- NIOX VERO DEVICE (Device) $19.87
- PNEUMOVAX 23 (Biological) $15.50
- ORALAIR (Biological) $10.58
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pediatrics Doctors in Gretna
Dr. Everett Brown, M.d, M.D
Pediatrics — Payments: $30,601
Pediatrics $30,601
Hai Nguyen, M.d, M.D
Pediatrics — Payments: $6,983
Pediatrics $6,983
Emily Bendlin, M.d, M.D
Pediatrics — Payments: $1,669
Pediatrics $1,669
Tina Anand, M.d, M.D
Pediatrics — Payments: $1,253
Pediatrics $1,253
Surbhi Dargan, Md, MD
Pediatrics — Payments: $1,023
Pediatrics $1,023
Grace Banuchi, Md, MD
Pediatrics — Payments: $851.83
Pediatrics $851.83